Chikashi Takeda, Executive Officer and CFO PLAY LIST from the beginning Consolidated Financial Results for the 3rd Quarter of Fiscal 2021 and Full‐Year Forecasts Disclaimer Highlights 01. Consolidated Financial Results and Business Review for the 3Q of Fiscal 2021 (FY Ending March 31, 2021) 3Q of Fiscal 2021 (1)Consolidated Financial Results Updates: January to December 3Q of Fiscal 2021 (2)Endoscopic Solutions Division(ESD) 3Q of Fiscal 2021 (3)Therapeutic Solutions Division(TSD) 3Q of Fiscal 2021 (4)Scientific Solutions Division(SSD) Statement of Financial Position Consolidated Cash Flows 02. Forecasts for Fiscal 2021 Fiscal 2021 Consolidated Forecasts Fiscal 2021 Forecasts by Business Segment 03. Transforming into a Truly Global Medtech Company Committed to Corporate Reforms Key Product Catalysts: Endoscopic Solutions Division(As of Feb.12, 2021) Acquired Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities Key Product Catalysts: Therapeutic Solutions Division(As of Feb. 12, 2021) Olympus Opportunities in Respiratory Olympus Approach to Reusable and Single-use Endoscope @ 04. Appendix Supplementary Materials: 3Qof Fiscal2021 Factors that AffectedConsolidated Operating Profit Supplementary Materials: 3Q of Fiscal 2021 Results by Segment Supplementary Materials: 3Q of Fiscal 2021 Discontinued Operation(IMD) Supplementary Materials: Expenditures etc. Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Back Next